Single-agent pemetrexed in patients with ALK-positive NSCLC: A retrospective analysis of investigator-reported outcomes

被引：0
|
作者：
Salgia, R.
Ou, S. I.
Riely, G.
Kim, D. W.
Shaw, A.
Wilner, K.
Tang, Y.
Polli, A.
Scagliotti, G. V.
机构：
来源：
CLINICAL CANCER RESEARCH | 2012年 / 18卷 / 03期
关键词：
D O I：
10.1158/1078-0432.12AACRIASLC-B31
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B31
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Crizotinib Outcomes in ALK-Positive Advanced NSCLC Patients with Brain Metastases
    Davis, Keith L.
    Kaye, James A.
    Iyer, Shrividya
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S376 - S377
  • [2] Diagnostics and Treatment of ALK-Positive NSCLC Patients - A Single Center Experience
    Pesek, Milos
    Grossmann, Petr
    Mukensnabl, Petr
    Krakorova, Gabriela
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S603 - S603
  • [3] Response Rate and Outcomes in Crizotinib Treated Advanced ALK-Positive NSCLC Patients
    Davis, Keith L.
    Kaye, James A.
    Iyer, Shrividya
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S411 - S412
  • [4] A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK-positive (ALK plus ) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ)
    Scagliotti, Giorgio
    Kim, Dong-Wan
    Shaw, Alice Tsang
    Ou, Sai-Hong Ignatius
    Riely, Gregory J.
    Gettinger, Scott N.
    Besse, Benjamin
    Thomas, Michael
    Salgia, Ravi
    Wilner, Keith D.
    Bartlett, Cynthia Huang
    Polli, Anna
    Gandara, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Retrospective analysis of clinical outcomes of early stage ALK-positive (ALK plus ) non-small cell lung cancer (NSCLC).
    Dagogo-Jack, Ibiayi
    Santini, Fernando
    Eng, Juliana
    Yeap, Beow Y.
    Izar, Benjamin
    Chin, Emily
    Litvak, Anya
    Jones, David Randolph
    Kris, Mark G.
    Shaw, Alice Tsang
    Gainor, Justin F.
    Chaft, Jamie E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
    Chang, Gee-Chen
    Yang, Tsung-Ying
    Chen, Kun-Chieh
    Hsu, Kuo-Hsuan
    Huang, Yen-Hsiang
    Su, Kang-Yi
    Yu, Sung-Liang
    Tseng, Jeng-Sen
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [7] A RETROSPECTIVE ANALYSIS ALK-POSITIVE NON-SMALL-CELL LUNG CARCINOMA (NSCLC)
    Pinto, I. G.
    Graziano, S.
    Gajra, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : E22 - E22
  • [8] ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
    Gee-Chen Chang
    Tsung-Ying Yang
    Kun-Chieh Chen
    Kuo-Hsuan Hsu
    Yen-Hsiang Huang
    Kang-Yi Su
    Sung-Liang Yu
    Jeng-Sen Tseng
    Scientific Reports, 10
  • [9] A LARGE RETROSPECTIVE ANALYSIS OF PEMETREXED (PEM) ACTIVITY IN PATIENTS (PTS) WITH ALK-POSITIVE (ALK plus ) NON-SMALL CELL LUNG CANCER (NSCLC) PRIOR TO CRIZOTINIB (CRIZ) TREATMENT
    Scagliotti, G.
    Kim, D. W.
    Shaw, A. T.
    Ou, S. I.
    Riely, G. J.
    Gettinger, S.
    Besse, B.
    Wilner, K.
    Tang, Y.
    Bartlett, C. H.
    ANNALS OF ONCOLOGY, 2012, 23 : 415 - 415
  • [10] ALK Inhibitor Sequencing and Outcomes Among ALK-Positive (ALK plus ) NSCLC Patients in the US Community Oncology Setting
    Waterhouse, D.
    Espirito, J.
    Chioda, M.
    Baidoo, B.
    Mardekian, J.
    Robert, N.
    Masters, E.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S559 - S560
12345